



MANAGEMENT TEAM

Christopher J. Moreau
Chief Executive Officer

Dr. Christopher Bryan, PhD
Vice President Research & Operations

James Kinley, CPA, CA
Chief Financial Officer & Director

Dr. Ahmed Khalil, PhD
Medical Director

BUSINESS ADVISORY BOARD

W. Bruce Rolands

MEDICAL & SCIENTIFIC ADVISORY BOARD

Dr. Mark Swaim, MD, PhD

Dr. Jacky Smith, MB, ChB, FRCP, PhD

Dr. Martin Kolb, MD

BOARD OF DIRECTORS

Harry J. F. Bloomfield, QC.

Christopher J. Moreau, CEO

Raj Attariwala, MD, PhD

Dr. Mark Williams, PhD.

U.S. Ambassador (Rtd)
Howard Gutman

STOCK INFORMATION

(July 21, 2022)

Shares O/S: 1.68 Million
Market Cap: C\$ 5.37 Million
Recent Price: C\$ 3.20

TRADING SYMBOLS

CSE: AGN
OTCQB: AGNPF
XFRA: AGWO

INVESTOR INQUIRIES

Christopher J. Moreau, CEO
604.398.4175
chris@algernonpharmaceuticals.com

HEAD OFFICE

Algernon Pharmaceuticals Inc.
Suite 400 - 601 West Broadway
Vancouver, BC, Canada, V5Z 4C2

CORPORATE PRESENTATION

COMPANY OVERVIEW

Algernon is a drug repurposing company, investigating drugs that have an established safety history for new disease applications, moving them efficiently and safely into new human trials, and seeking new regulatory approvals in billion dollar global disease markets. Repurposing offers several benefits over traditional drug development including a reduction in investment and risk (repurposed compounds have a much lower risk of failing in human trials as a result of safety issues), shorter research periods and a longer active patent life.

Our program specifically investigates compounds that have never been approved in the U.S. or Europe. We protect our lead compounds with method of use, dosing and new formulation patents, as well as composition of matter patents that include derivatives and analogues. The Algernon model is highly capital efficient and the company has assembled an experienced management team, a globally recognized medical and scientific advisory board, and a business advisory board.

ALGERNON PHARMACEUTICALS CLINICAL PIPELINE*

CANDIDATE	INDICATION	DEVELOPMENT STAGE
		PRECLINICAL PHASE 1 PHASE 2 PHASE 3 REGULATORY REVIEW
Inflammatory Disorders		
IFENPRODIL	Idiopathic Pulmonary Fibrosis & Chronic Cough	Phase 2 Pilot Study Ongoing Data - Q2, 2022
REPIRINAST	Chronic Kidney Disease	Began CGMP Manufacturing - Q1, 2022 Begin Phase 1 - Q4, 2022
Cerebrovascular Disorders		
DMT N, N-DIMETHYLTRYPTAMINE	Stroke	Begin Phase 1 - Q3, 2022 Begin Phase 2 - Acute Stroke Q1, 2023
Oncology**		
IFENPRODIL	Pancreatic Cancer	Begin Phase 1 - Q4, 2022
IFENPRODIL	Small Cell Lung Cancer	Begin Phase 1 - Q4, 2022

* In addition to the above, the Company is considering repurposing additional drug candidates currently in the preclinical stage

** The Company is seeking non-dilutive funding mechanisms in order to advance its oncology research programs.

ALGERNON'S LEAD CLINICAL RESEARCH PROGRAMS

IDIOPATHIC PULMONARY FIBROSIS (IPF) AND CHRONIC COUGH

Algernon is investigating Ifenprodil in a proof-of-concept Phase 2 human trial to determine the efficacy of Ifenprodil in the preservation of lung function in IPF patients (including biomarkers of fibrosis) with chronic cough. There are 7 sites in total participating in the study with 5 located in Australia and 2 in New Zealand.

Ifenprodil has been shown to mediate anti-inflammatory responses and reduce pulmonary fibrosis in a murine model of IPF. In addition, Ifenprodil significantly both reduced cough frequency and delayed onset in a guinea pig acute cough model.

* The global stroke treatment market is expected to reach a value of US\$ 15 Bn by the year 2027.

STROKE

Algernon has established a clinical research program for the treatment of stroke focused on AP-188 ("N,N-Dimethyltryptamine or DMT"), a known psychedelic compound that is part of the tryptamine family (other drugs in the tryptamine family include psilocybin and psilocin). Algernon plans to be the first company globally to investigate DMT for stroke in humans and is planning to begin a Phase 1 clinical trial in Q1, 2022.

* The IPF market is expected to reach a value of US\$ 3.2 Bn by 2025.

* The chronic cough market is expected to reach a value of US\$ 9.8 Bn by 2027.



RECENT DEVELOPMENTS

JULY 18, 2022

Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough

JULY 11, 2022

Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study

JULY 07, 2022

Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study

JULY 05, 2022

Algernon Pharmaceuticals Discloses Novel DMT Salt Patent Strategy Includes Bioactive Nicotinate and Pamoate

JUNE 22, 2022

Algernon Pharmaceuticals Announces Issuance of Patent for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis

JUNE 21, 2022

Algernon Announces Patients Requested Ongoing Supply of Ifenprodil after IPF and Chronic Cough Phase 2 Study Ended

JUNE 13, 2022

Algernon Pharmaceuticals Announces Database Lock in Phase 2 Study of IPF and Chronic Cough

APRIL 26, 2022

Algernon Pharmaceuticals Announces Lead Chronic Kidney Disease Drug Repirinast Reduced Fibrosis by 56% in a Preclinical NASH Study

CHRONIC KIDNEY DISEASE (CKD)

Algernon's lead compound for the treatment and management of chronic kidney disease ("CKD") is Repirinast, an orally administered small molecule. Repirinast acts on mast cells and inhibits the release of chemical mediators by IgE-related antigen antibody interactions. Repirinast, in a unilateral ureteral obstruction mouse model of kidney fibrosis reduced fibrosis by 50% with statistical significance. Algernon has begun manufacturing a cGMP supply of the drug and is planning a phase 1 study in Q4, 2022.

* The global CKD drug market is expected to reach value of US\$15.8 Bn by the end of 2024.

ALGERNON CEO INTERVIEWS



Christopher J. Moreau
Chief Executive Officer

- **ALGERNON PHARMACEUTICALS STUDY OF IFENPRODIL FOR THE TREATMENT OF IPF AND CHRONIC COUGH REACHES KEY STAGE**
- **ALGERNON PHARMACEUTICALS PROVIDES UPDATE ON CHRONIC KIDNEY DISEASE RESEARCH PROGRAM WITH NP-251**
- **BUSINESS TELEVISION - ALGERNON'S DMT/STROKE CLINICAL PROGRAM**
- **STREETWISE LIVE! - CAN THE PSYCHEDELIC DRUG DMT TAKE ALGERNON PHARMACEUTICALS TO THE NEXT LEVEL?**

ALGERNON IN THE NEWS

- **STREETWISE REPORTS - ALGERNON PHARMACEUTICALS LOOKS TO U.S. FOR HELP FIGHTING STROKES**
- **MARKET ONE - RETHINKING DMT: ALGERNON PHARMACEUTICALS' NOVEL APPROACH TO STROKE TREATMENT**

ALGERNON YEAR-TO-DATE PRICE HISTORY



CLICK FOR A REAL TIME QUOTE

READ MORE NEWS RELEASES

RESEARCH CAPITAL
CORPORATION

André Uddin, Ph.D.
Managing Director Healthcare
auddin@mackieresearch.com

Algernon Pharmaceuticals is covered by Research Capital Corporation. Please note that any opinions, estimates or forecasts regarding Algernon Pharmaceuticals' performance made by this analyst, or any other, is theirs alone and do not represent the opinions, forecasts or predictions of the Company.